Search results for "lipoproteínas"

showing 4 items of 4 documents

Mutual influences between Nitric Oxide and Paraoxonase 1

2019

Este artículo se ha publicado de forma definitiva en: https://www.mdpi.com/2076-3921/8/12/619 Este artículo pertenece al número especial "Paraoxonase in Oxidation and Inflammation". One of the best consolidated paradigms in vascular pharmacology is that an uncontrolled excess of oxidizing chemical species causes tissue damage and loss of function in the endothelial and subendothelial layers. The fact that high-density lipoproteins play an important role in preventing such an imbalance is integrated into that concept, for which the expression and activity of paraoxonases is certainly crucial. The term paraoxonase (aryldialkyl phosphatase, EC 3.1.8.1) encompasses at least three distinct isofo…

0301 basic medicineAntioxidantantioxidantPhysiologymedicine.medical_treatmentClinical BiochemistryPhosphataseCellOxidative phosphorylationReview030204 cardiovascular system & hematologyBiochemistryNitric oxide03 medical and health scienceschemistry.chemical_compound0302 clinical medicinenitric oxidemedicinevascular inflammationVasculitis - Tratamiento.Molecular Biologychemistry.chemical_classificationreactive oxygen speciesReactive oxygen speciesÓxido nítrico - Uso terapéutico.biologyParaoxonaseserum lipoproteinCell BiologyParaoxonase - Therapeutic use.Paraoxonasa - Uso terapéutico.paraoxonaseNitric oxide synthaseLipoproteínas.030104 developmental biologymedicine.anatomical_structurechemistryBiochemistryAntioxidantes.biology.proteinVasculitis - Treatment.Antioxidants.Nitric oxide - Therapeutic use.Lipoproteins.
researchProduct

Indicaciones de los inhibidores de PCSK9 en la práctica clínica. Recomendaciones de la Sociedad Española de Arteriosclerosis (SEA), 2019

2019

Resumen Un grupo de expertos convocado por la Sociedad Espanola de Arteriosclerosis (SEA) se ha encargado de actualizar el documento de la SEA sobre las indicaciones de los inhibidores de PCSK9 (iPCSK9) en la practica clinica publicadas en 2016. Esta actualizacion es necesaria porque en el periodo transcurrido hasta la actualidad se han publicado los resultados de los ensayos clinicos realizados a gran escala con iPCSK9 que demuestran que, ademas de su alta potencia para disminuir el colesterol aterogenico, disminuyen el riesgo de presentar episodios de enfermedad cardiovascular aterosclerotica en los pacientes con enfermedad tanto estable como reciente, y con un alto grado de seguridad. La…

Inhibidores de la proproteína convertasa subtilisina kexina 9ArteriosclerosisEnfermedad cardiovascularFamilial hypercholesterolemiaClinical indicationsLow density lipoprotein030204 cardiovascular system & hematologyArteriosclerosi03 medical and health sciencesLipoproteínas de baja densidad0302 clinical medicineIndicaciones clínicasTratamientoPharmacology (medical)030212 general & internal medicineConsensus documentHipercolesterolemia familiarNumber needed to treatCardiovascular diseaseDocumento de consensoTreatmentArterioesclerosiCholesterolProprotein convertase subtilisin kexin 9 inhibitorsCardiology and Cardiovascular MedicineColesterolNúmero necesario a tratar
researchProduct

Role of HDL function and LDL atherogenicity on cardiovascular risk: a comprehensive examination

2019

[Background] High-density lipoprotein (HDL) functionality and low-density lipoprotein (LDL) atherogenic traits can describe the role of both particles on cardiovascular diseases more accurately than HDL- or LDL-cholesterol levels. However, it is unclear how these lipoprotein properties are particularly affected by different cardiovascular risk factors.

MalePhysiologyhumanosLipoproteïnesBlood PressureCardiovascular Medicine030204 cardiovascular system & hematologyOxidacióBiochemistryVascular Medicinelipoproteínas616.1 - Patologia del sistema circulatori dels vasos sanguinis. Trastorns cardiovasculars:Ciencias de la Salud::Cardiología [Materias Investigacion]Endocrinology0302 clinical medicineRisk FactorsSex factorsSistema cardiovascular--MalaltiesMedicine and Health SciencesMedicine030212 general & internal medicinemediana edadancianoMultidisciplinaryQChemical ReactionsAge FactorsRMiddle AgedadultoLipidsBody FluidsLipoproteins LDLLipoproteïnes de densitat baixaChemistryBloodCholesterolCardiovascular DiseasesPhysical SciencesHypertensiondiabetes mellitusMedicineFemalelipids (amino acids peptides and proteins)AnatomyLipoproteins HDLColesterolResearch ArticleAdultEndocrine DisordersScienceLipoproteinsdislipidemiasenfermedades cardiovascularesBlood Plasma03 medical and health sciencesSex FactorsOxidationHumansfactores de riesgoAgedDyslipidemiasbusiness.industryCholesterol HDLBiology and Life SciencesProteinsCholesterol LDLAtherosclerosisSistema cardiovascular -- Malalties -- Factors de riscCross-Sectional StudiesLipoproteïnes de densitat altaDyslipidemiaDiabetes Mellitus Type 2Metabolic DisordersaterosclerosisbusinessHumanitiesestudios transversales
researchProduct

Familial hypercholesterolaemia: A global call to arms

2015

Familial Hypercholesterolaemia (FH) is the commonest autosomal co-dominantly inherited condition affecting man. It is caused by mutation in one of three genes, encoding the low-density lipoprotein (LDL) receptor, or the gene for apolipoprotein B (which is the major protein component of the LDL particle), or in the gene coding for PCSK9 (which is involved in the degradation of the LDL-receptor during its cellular recycling). These mutations result in impaired LDL metabolism, leading to life-long elevations in LDL-cholesterol (LDL-C) and development of premature atherosclerotic cardiovascular disease (ASCVD) [1], [2] and [3]. If left untreated, the relative risk of premature coronary artery d…

PathologyApolipoprotein BDisease030204 cardiovascular system & hematologymedicine.disease_causeGlobal HealthDISEASEDoenças Cardio e Cérebro-vasculares0302 clinical medicineHyperlipoproteinemia Type IISocieties MedicalRISK0303 health sciencesMutationbiology3. Good healthPREVALENCEEuropelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineFamilial hypercholesterolaemiaLife Sciences & Biomedicinemedicine.medical_specialtyHeterozygote1102 Cardiovascular Medicine And HaematologyHyperlipoproteinemia Type II03 medical and health sciencesInternal medicinemedicineHumans030304 developmental biologyScience & Technologybusiness.industryGUIDANCEPCSK9Heterozygote advantage1103 Clinical SciencesEndocrinologyPeripheral Vascular DiseaseCardiovascular System & HematologyReceptors LDLRECEPTORES DE LIPOPROTEÍNASRelative riskMutationbiology.proteinCardiovascular System & CardiologyFamilial HypercholesterolaemiabusinessCLINICIANLipoprotein
researchProduct